Literature DB >> 20406967

Tumor-initiated inflammation overrides protective adaptive immunity in an induced melanoma model in mice.

Saïdi M Soudja1, Maria Wehbe, Amandine Mas, Lionel Chasson, Céline Powis de Tenbossche, Ivo Huijbers, Benoît Van den Eynde, Anne-Marie Schmitt-Verhulst.   

Abstract

We studied the effect of the immune system on two differentially aggressive melanomas developing in mice on conditional deletion of the INK4A/ARF tumor suppressor gene, with concomitant expression of oncogene H-Ras(G12V) and a natural cancer-germline tumor antigen (TA). "Slow progressor" melanomas contained no activated T lymphocytes (TL). In contrast, "aggressive" melanomas were infiltrated by activated TLs lacking effector molecules and expressing high levels of PD-1, indicating an exhausted phenotype. Aggressive melanomas were also infiltrated by immature myeloid cells (IMC). Infiltration was associated with local inflammation and systemic Th2/Th17-oriented chronic inflammation that seemed to impair further activation of TLs, as tumor-specific T cells adoptively transferred into mice bearing aggressive melanomas were poorly activated and failed to infiltrate the melanoma. This immunosuppression also led to the incapacity of these mice to reject inoculated TA-positive tumors, in contrast to slow-progressing melanoma-bearing mice, which were responsive. To test the role of adaptive immunity in tumor progression, we induced melanomas in immunodeficient RagKO compound mice. These mice developed aggressive but not slow-progressing melanomas at a higher frequency and with a shorter latency than immunocompetent mice. Immunodeficient mice also developed abnormal inflammation and infiltration of IMCs in a manner similar to immunocompetent mice, indicating that this phenotype was not dependent on adaptive immunity. Therefore, tumor-intrinsic factors distinguishing the two melanoma types control the initiation of inflammation, which was independent of adaptive immunity. The latter delayed development of aggressive melanomas but was overridden by inflammation. (c)2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20406967     DOI: 10.1158/0008-5472.CAN-09-4354

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells.

Authors:  Marilyn Giordano; Romain Roncagalli; Pierre Bourdely; Lionel Chasson; Michel Buferne; Sho Yamasaki; Rudi Beyaert; Geert van Loo; Nathalie Auphan-Anezin; Anne-Marie Schmitt-Verhulst; Grégory Verdeil
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

2.  Training the Defense System for Modern-Day Warfare: The Horizons for Immunotherapy and Vaccines for Cancer.

Authors:  Narendra Kumar; Jayshree Mishra; Sohel H Quazi
Journal:  J immunodefic Disord       Date:  2012-07-21

Review 3.  Tumor cell plasticity: the challenge to catch a moving target.

Authors:  Sarah Schwitalla
Journal:  J Gastroenterol       Date:  2014-02-25       Impact factor: 7.527

4.  MAF drives CD8+ T-cell exhaustion.

Authors:  Grégory Verdeil
Journal:  Oncoimmunology       Date:  2015-08-31       Impact factor: 8.110

5.  Unleashing antitumor T-cell activation without ensuing autoimmunity: the case for A20-deletion in adoptive CD8+ T-cell therapy.

Authors:  Grégory Verdeil; Anne-Marie Schmitt-Verhulst
Journal:  Oncoimmunology       Date:  2014-12-15       Impact factor: 8.110

Review 6.  Cooperativity of adaptive and innate immunity: implications for cancer therapy.

Authors:  Anil Shanker; Francesco M Marincola
Journal:  Cancer Immunol Immunother       Date:  2011-06-09       Impact factor: 6.968

7.  Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion.

Authors:  Marilyn Giordano; Coralie Henin; Julien Maurizio; Claire Imbratta; Pierre Bourdely; Michel Buferne; Lukas Baitsch; Laurent Vanhille; Michael H Sieweke; Daniel E Speiser; Nathalie Auphan-Anezin; Anne-Marie Schmitt-Verhulst; Grégory Verdeil
Journal:  EMBO J       Date:  2015-07-02       Impact factor: 11.598

Review 8.  Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis.

Authors:  Jayshree Mishra; Joseph Drummond; Sohel H Quazi; Satya Sridhar Karanki; J J Shaw; Ben Chen; Narendra Kumar
Journal:  Crit Rev Oncol Hematol       Date:  2012-10-23       Impact factor: 6.312

Review 9.  Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

Authors:  Michael Hölzel; Anton Bovier; Thomas Tüting
Journal:  Nat Rev Cancer       Date:  2013-03-28       Impact factor: 60.716

10.  Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells.

Authors:  Arnaud Pommier; Alexandra Audemard; Aurélie Durand; Renée Lengagne; Arnaud Delpoux; Bruno Martin; Laetitia Douguet; Armelle Le Campion; Masashi Kato; Marie-Françoise Avril; Cédric Auffray; Bruno Lucas; Armelle Prévost-Blondel
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.